One of these EphA4 antagonists is the KYL peptide, which has been extensively characterized and shown to be effective in several in vitro assays as well as in in vivo spinal cord injury and ALS models (11, 19, 23, 24), suggesting the potential of an EphA4-based therapeutic approach. The gene discussed is EPHA4; the disease is amyotrophic lateral sclerosis.